To Be Discontinued Injection Antiviral
Palivizumab Injection · 394 days since initial FDA posting
Brand: SYNAGIS
FDA lists Palivizumab Injection as To Be Discontinued (Swedish Orphan Biovitrum AB).
No availability text on this FDA row.
Palivizumab Injection: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Palivizumab Injection
- Manufacturer
- Swedish Orphan Biovitrum AB
- Dosage Form
- Injection
- Presentation
- Synagis, Injection, 100 mg/1 mL (NDC 66658-231-01)
- Package NDC
- 66658-231-01
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Aug 13, 2025
- Last Updated
- Aug 13, 2025
- Therapeutic Category
- Antiviral
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Discontinuation of the manufacture of the drug. Product expected to be available through July 2026.
Nearby, Other Palivizumab Shortage Records
FDA reason on file: Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.